Literature DB >> 34762234

Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review.

Mushtaq Ahmad Wani1, Devendra Kumar Dhaked2.   

Abstract

The terminal oxidases of the oxidative phosphorylation pathway play a significant role in the survival and growth of M. tuberculosis, targeting these components lead to inhibition of M. tuberculosis. Many drug candidates targeting various components of the electron transport chain in M. tuberculosis have recently been discovered. The cytochrome bc1-aa3 supercomplex is one of the most important components of the electron transport chain in M. tuberculosis, and it has emerged as the novel target for several promising candidates. There are two cryo-electron microscopy structures (PDB IDs: 6ADQ and 6HWH) of the cytochrome bc1-aa3 supercomplex that aid in the development of effective and potent inhibitors for M. tuberculosis. In recent years, a number of potential candidates targeting the QcrB subunit of the cytochrome bc1 complex have been developed. In this review, we describe the recently identified inhibitors that target the electron transport chain's terminal oxidase enzyme in M. tuberculosis, specifically the QcrB subunit of the cytochrome bc1 complex.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cytochrome bc 1 complex; Oxidative phosphorylation pathway; Q203; QcrB inhibitors; QcrB subunit; Terminal oxidase

Mesh:

Substances:

Year:  2021        PMID: 34762234     DOI: 10.1007/s11030-021-10335-y

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  105 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

2.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

3.  Emerging opportunities of exploiting mycobacterial electron transport chain pathway for drug-resistant tuberculosis drug discovery.

Authors:  Kuldeep K Roy; Mushtaq Ahmad Wani
Journal:  Expert Opin Drug Discov       Date:  2019-11-27       Impact factor: 6.098

Review 4.  Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence.

Authors:  Issar Smith
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 5.  Thiacetazone--avoid like poison or use with care?

Authors:  P Nunn; J Porter; P Winstanley
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Sep-Oct       Impact factor: 2.184

6.  Diagnosis and management of miliary tuberculosis: current state and future perspectives.

Authors:  Sayantan Ray; Arunansu Talukdar; Supratip Kundu; Dibbendhu Khanra; Nikhil Sonthalia
Journal:  Ther Clin Risk Manag       Date:  2013-01-08       Impact factor: 2.423

Review 7.  Tuberculosis and HIV co-infection.

Authors:  Andrzej Pawlowski; Marianne Jansson; Markus Sköld; Martin E Rottenberg; Gunilla Källenius
Journal:  PLoS Pathog       Date:  2012-02-16       Impact factor: 6.823

8.  Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.

Authors:  Meeta J Advani; Imran Siddiqui; Pawan Sharma; Hemalatha Reddy
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

Review 9.  Genitourinary tuberculosis: historical and basic science review: past and present.

Authors:  Thaddaeus Zajaczkowski
Journal:  Cent European J Urol       Date:  2012-12-11

Review 10.  Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis.

Authors:  Diana Machado; Miriam Girardini; Miguel Viveiros; Marco Pieroni
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640

View more
  1 in total

Review 1.  Recent Advances in Structural Studies of Cytochrome bd and Its Potential Application as a Drug Target.

Authors:  Thorsten Friedrich; Daniel Wohlwend; Vitaliy B Borisov
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.